Antibody-targeted T cells and natural killer cells for cancer immunotherapy.

ABSTRACT:

Background

Adoptive cell cancer therapies aim to re-engineer a patient's immune cells to mount an anti-cancer response. Chimeric antigen receptor T and natural killer cells have been engineered and proved successful in treating some cancers; however, the genetic methods for engineering are laborious, expensive, and inefficient and can cause severe toxicities when they over-proliferate.

Results

We examined whether the cell-killing capacity of activated T and NK cells could be targeted to cancer cells by anchoring antibodies to their cell surface. Using metabolic glycoengineering to introduce azide moieties to the cellular surface, we covalently attached a dibenzocyclooctyne-modified antibody using the strain-promoted alkyne azide cycloaddition reaction, creating antibody-conj

SUBMITTER: Sutherland AR 

PROVIDER: S-EPMC11488284 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature